Glenmark Pharmaceuticals has initiated patient enrollment in India for a multi-country Phase 3 clinical trial of its drug Trastuzumab rezetecan. This trial targets platinum-resistant ovarian cancer and is a step towards building its global oncology pipeline.
Glenmark Pharmaceuticals Advances Ovarian Cancer Drug Trial
Glenmark Pharmaceuticals has commenced patient enrollment in India for a multi-country Phase 3 clinical trial of its antibody drug conjugate (ADC), Trastuzumab rezetecan (SHR-A1811). This trial focuses on patients with HER2-expressing platinum-resistant ovarian cancer (PROC). ## What just happened The company has started enrolling patients in India for a pivotal Phase 3 clinical trial of Trastuzumab rezetecan, following approval from the Drugs Controller General of India (DCGI). This marks a significant step in the drug's development for ovarian cancer. ## Why this matters This trial is crucial for Glenmark's strategy to develop a differentiated oncology pipeline for global markets. Successful completion could lead to new treatment options for patients with resistant ovarian cancer and enhance the company's revenue potential. ## The backstory Glenmark entered into an exclusive collaboration and license agreement with Jiangsu Hengrui Pharmaceuticals in September 2025 for Trastuzumab rezetecan. The drug has already shown clinical progress and received designations in China for other cancer types. ## What changes now Initiation of the Phase 3 trial in India allows Glenmark to gather crucial efficacy and safety data in a new patient population. The company also plans to expand the trial to Australia and South Korea, subject to regulatory approvals. ## Risks to watch Clinical trial outcomes are inherently uncertain. Regulatory approvals in new markets and the drug's performance against existing treatments will be key challenges. The success of the licensor's ongoing trial in China also provides a benchmark. ## Peer comparison Glenmark is competing in the growing antibody drug conjugate market. Companies like Seagen (now Pfizer), AstraZeneca, and Daiichi Sankyo have significant portfolios in ADCs, particularly for HER2-expressing cancers. ## Context metrics (time-bound) The company announced this Phase 3 trial initiation on June 11, 2024. Enrollment in India has begun, with plans to expand to Australia and South Korea. ## What to track next Investors will be watching for updates on patient enrollment numbers, the timeline for trial completion, and the eventual readout of clinical data. Expansion to Australia and South Korea is also a key development to monitor.
Disclaimer:This article is published for informational purposes only. While reasonable efforts are made to ensure accuracy, completeness, and timeliness, readers are encouraged to independently verify information before making any decisions based on the content. The views and information presented are subject to editorial review and may be updated without notice.
